Manejo quirúrgico del cáncer epitelial de ovario: Guía de práctica clínica de la Asociación Colombiana de Ginecólogos Oncólogos (ASCGO)

Grupo Desarrollador de la Guía

Resumen


Introducción: el cáncer epitelial de ovario constituye la primera causa de muerte por cáncer ginecológico a nivel mundial. En Colombia cada año se presentan 8,7 casos nuevos por cada 100.000 mujeres y se registran más de 800 muertes por causa de esta enfermedad. La cirugía constituye el pilar de manejo de las pacientes con cáncer epitelial de ovario, su realización oportuna y la adecuada combinación con otras estrategias terapéuticas busca erradicar la enfermedad o, en los estados avanzados, lograr volúmenes tumorales microscópicos para mejorar el pronóstico. El objetivo de este trabajo consiste en desarrollar recomendaciones basadas en la evidencia para el diagnóstico y tratamiento quirúrgico integral del cáncer epitelial de ovario en población colombiana.

Materiales y métodos:guía de práctica clínica basada en la evidencia, desarrollada por un panel de expertos de la Asociación Colombiana de Ginecólogos Oncólogos. La Sociedad definió y validó un total de 33 preguntas de interés para el manejo quirúrgico integral. Se llevó a cabo una revisión de literatura de guías de práctica clínica y se actualizó la evidencia de las guías fuente usando revisiones de literatura y estudios primarios experimentales y observacionales acordes con la naturaleza de cada pregunta. Finalmente, se discutieron y validaron las recomendaciones en la Asociación mediante un método participativo tipo panel de expertos.

Resultados: se resumen recomendaciones basadas en la mejor evidencia disponible para la detección temprana y el diagnóstico del cáncer epitelial de ovario, el manejo quirúrgico en estados tempranos y avanzados de la enfermedad, el seguimiento y manejo de las recaídas, así como el manejo con intención paliativa.

Conclusiones: esta GPC fue desarrollada utilizando procedimientos sistemáticos y la mejor evidencia disponible. Se espera que tenga un impacto positivo en el manejo y los desenlaces de las pacientes que padecen de esta enfermedad.


Palabras clave


neoplasias ováricas; diagnóstico; procedimientos quirúrgicos de citorreducción; Guía de Práctica Clínica

Texto completo:

PDF

Referencias


Wei W, Dizon D, Vathipadiekal V, Birrer MJ. Ovarian Cancer: genomic analysis. Annals of Oncology. 2013;24(suppl10):S7-S10.

Ulusoy S, AKbayir O, Nomanoglu C, Ulusoy N, Odabas E, Gulkilik A. The risk of malignancy index in discrimination of adnexal masses. Int J Gynaecol Obstet. 2007;96:186-91.

Instituto Nacional de Cancerología. Estadísticas | Instituto Nacional de Cancerología [Internet]. 2013 [cited 2015 Sept 9]. Disponible en: http://www.cancer.gov.co/content/estadisticas

Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am. 2012;26:93-109.

Tavassoli FA, Devilee P. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs.Lyon: IARC Press; 2003.

Colombo N, VanGorp T, Parma G, Amant F, Gatta G, Sessa N, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006;60:159-79.

Rufford BD, Jacobs IJ, Menon U. Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG. 2007;114:59-64.

Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121:615-9.

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26-31.

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Eng J Med. 2010;363:943-53.

Asociación Colombiana de Ginecólogos Oncólogos. Instituto para la Evaluación de la Calidad y Atención en Salud (IECAS). Guía de práctica clínica (GPC) para el manejo quirúrgico del cáncer epitelial de ovario en Colombia. Bogotá. En proceso de publicación electrónica.

Guidelines International Network. G-I-N Guidelines International Network [Internet]. 2013 [cited 2015 Sept 8]. Disponible en: http://www.g-i-n.net/

Agency for Healthcare Research and Quality. National Guideline Clearinghouse [Internet] [visitado 2015 Sept 9]. Disponible en: http://www.guideline.gov/

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE Next Steps Consortium; AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182:E839-42.

National Institute of Clinical Excellence NICE. Ovarian cancer: the recognition and initial management of ovarian cancer. Wales; 2011.

Moyer VA, Services USP, Force T. Clinical Guideline Screening for Ovarian Cancer: US Preventive Services Task Force OF. 2012;157(12).

National Breast and Ovarian Cancer Centre. Recommendations for management of women at high risk of ovarian cancer; 2011.

Scottish Intercollegiate Guidelines Network (SIGN). Management of epithelial ovarian cancer. Edinburgh; 2013 [visitado 2015 Sept 9]. Disponible en: http://www.sign.ac.uk

Royal College of Obstetricians and Gynaecologist. Management of Suspected Ovarian Masses in Premenopausal Women. Green-top Guideline No. 62 RCOG/BSGE; 2011.

National Institute of Clinical Excellence NICE. Ovarian Cancer : Evidence Update January 2013. A summary of selected new evidence relevant to NICE clinical guideline 122, “The recognition and initial management of ovarian cancer” (2011) Evidence. Manchester; 2013.

National Institute of Clinical Excellence NICE. Quality standard for ovarian cancer. Manchester; 2012.

National Institute of Clinical Excellence NICE. Ovarian cancer overview. NICE Pathways [Internet]. Manchester; 2014 [visitado 2015 Sept. 9]. Disponible en: http://pathways.nice.org.uk/pathways/ovariancancer

National Comprehensive Cancer Network. Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 3.2014; 2014.

Ministerio de Salud. Guía clínica AUGE Ovario Epitelial. Santiago de Chile; 2013.

Alberta Provincial Gynecologic Oncology Tumour Team. Clinical practice guideline Gyne-005, version 3. Epithelial ovarian, fallopian tube, and primary peritoneal cancer; 2013.

Alberta Provincial Gynecologic Oncology Tumour Team. Clinical practice guideline Br-011, version 2. Risk reduction and surveillance strategies for individuals at high genetic risk for breast and ovarian cancer; 2011.

Dodge J, Covens A, Lacchetti C, Elit L, Le T, Fung MFK. Management of a Suspicious Adnexal Mass. Toronto; 2011.

Jelovac D, Armstrong DK. Recent Progress in the Diagnosis and Treatment of Ovarian Cancer. CA Cancer J Clin. 2011;61:183-203.

Holschneider CH, Berek JS. Ovarian Cancer: Epidemiology, Biology, and Prognostic Factors. Semin Surg Oncol. 2000;19:3-10.

Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385-94.

Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Høgdall E, et al. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control. 2013;24:989-1004.

Mørch LS, Andreasen AH, Krüger-kjær S. Hormone Therapy and Ovarian Cancer. JAMA. 2009;302:298-305.

Mørch LS, Løkkegaard E, Andreasen AH, Kjaer SK, Lidegaard O. Hormone therapy and different ovarian cancers: a national cohort study. Am J Epidemiol. 2012;175:1234-42.

van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumors after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456-65.

Flam F, Einhorn N, Sjövall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1988;27:53-7.

Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of Ovarian Cancer. Obstet Gynecol. 2001;98:212-7.

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109:221-7.

Buys SS, Patridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295-303.

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378-83.

Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG. 2005;112:857-65.

Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008;115:1008-14.

Friedman GD, Skilling JS, Udaltsova NV, Smith LH. Early symptoms of ovarian cancer: a case-control study without recall bias. Fam Pract. 2005;22:548-53.

Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA.2004;291:2705-12.

Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ.2009;339:b2998.

Kim MK, Kim K, Kim SM, Kim JW, Park NH, Song YS, et al. A hospital-based case-control study of identifying ovarian cancer using symptom index. J Gynecol Oncol.2009;20:238-42.

Lurie G, Thompson PJ, McDuffie KE, Carney ME, Goodman MT. Prediagnostic symptoms of ovarian carcinoma: a case-control study. Gynecol Oncol. 2009;114:231-6.

Olsen CM, Cnossen J, Green AC, Webb PM. Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol. 2007;28:376-80.

Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 2010;102:222-9.

Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol. 2001;83:466-71.

Webb PM, Purdie DM, Grover S, Jordan S, Dick ML, Green AC. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol. 2004;92:232-9.

Lancaster JM, Powell CB, Chen L, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136:3-7.

Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol. 2012;126:157-66.

Geomini P, Kruitwagen R, Bremer G, Cnossen J, Mol B. The Accuracy of Risk Scores in Predicting Ovarian Malignancy. A sistematic review. Obstet Gynecol. 2009;113:384-94.

Kaijser J, Sayasneh A, van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, et al. Presurgical diagnosis of adnexal tumors using mathematical models and scoring systems: a systematic review and meta-analysis. Hum Reprod Update.2014;20:449-62.

Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, et al. Management of Adnexal Mass. Evid Rep Technol Assess. 2006:1-145.

Testa A, Kaijser J, Wynants L, Fischerova D, van Holsbeke C, Franchi D, et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. Br J Cancer. 2014;111:680-8.

Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumor Biol. 2014;35:6127-38.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99-105.

Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol [Internet]. 2007;62:328-34.

Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol. 2007;105:801-12.

Du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol. 2009;112:422-36.

Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol. 2005;99:447-61.

American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetriciangynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100:1413-16.

Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C, et al. Validation of Referral Guidelines for Women with Pelvic Masses. Am Coll Obstet Gynecol. 2005;105:35-41.

Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl). 2012;8:543-55.

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-92.

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-75.

Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, et al. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can. 2007;29:45-60.

Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene. 2006;25:5825-31.

Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28:222-31.

Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol. 2004;22:1045-54.

Rebbeck TR, Kauff ND, Domchek SM. Metaanalysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80-7.

Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, et al. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014;12:1326-38.

Movahedi S, Baker PM, Gilks B, Soslow RA, Oliva E. Protocol for the Examination of Specimens from Patients with Carcinoma of the Ovary. College of American Pathologists (CAP); 2009 [visitado 2015 Sept 9]. Disponible en: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2009/Ovy_09protocol.pdf

Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64.

Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-22.

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingooophorectom in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-15.

Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475-9.

Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491-6.

Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol.2010;116:733-43.

Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547-53.

Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150.

Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front Oncol. 2014;4:21.

Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Pro-phylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol. 2013;129:448-51.

Finch A, Narod SA. Quality of life and health status after prophylactic sal-pingo-oophorectomy in women who carrya BRCA mutation: A review. Maturitas.2011;70:261-5.

Finch A, Metcalfe KA, Chiang J, Elit L, McLaughlin J, Springate C, et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology.2013; 22:212-9.

Pezaro C, James P, McKinley J, Shanahan M, Young MA, Mitchell G. The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause. Fam Cancer.2012;11:403-10.

Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, et al. Reproductive and hormonal factors, and ovarian cáncer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev.2009;18:601-10.

Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausa women: a population-based cohort study. Lancet Oncol 2006;7:821-8.

Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol.2013;121:709-16.

Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol.2013;121:14-24.

Dell’ Anna T, Signorelli M, Benedetti-Panici P, Maggioni A, Fossati R, Fruscio R, et al. Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial. Br J Cancer [Internet]. 2012 [visitado 2015 Sept 9]; 107:785-92. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3425968&tool=pmcentrez&rendertype=abstract

Lawrie T, Medeiros LRF, Rosa DD, Bozzetti MC, da Rosa MI, Edelweiss MI, et al. Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer. Cochrane Database Syst Rev. 2008;(4):CD005344.

Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a metaanalysis of multiple epidemiology studies. Jpn J Clin Oncol [Internet]. 2014 [visitado 2015 Sept 9]; 45:49-60. Disponible en: http://jjco.oxfordjournals.org/cgi/doi/10.1093/jjco/hyu175

Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane database Syst Rev.2012;(3):CD004706.

Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, et al. Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2010;20:520-8.

Maggioni A, Benedetti Panici P, Dell’Anna T, Landoni F, Lissoni A, Pellegrino A, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95:699-704.

Yokoyama Y, Sakamoto T, Sato S, Saito Y. Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol. 1999;20:361-6.

Chan JK, Munro EG, Cheung MK, Husain A, Teng NN, Berek JS, et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol. 2007;109:12-9.

Vergote I, Du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol. 2013;128:6-11.

Morrison J, Haldar K, Kehoe S, Ta L. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer (Review). Cochrane Database Syst Rev. 2014;(8. Art.No.: CD005343).

Ghezzi F, Cromi A, Uccella S, Bergamini V, Tomera S, Franchi M, et al. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol. 2007;105:409-13.

Lécuru F, Desfeux P, Camatte S, Bissery A, Blanc B, Querleu D. Impact of initial surgical access on staging and survival of patients with stage I ovarian cancer. Int J Gynecol Cancer. 2006;16:87-94.

Park J-Y, Bae J, Lim MC, Lim SY, Seo S-S, Kang S, et al. Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety. Int J Gynecol Cancer. 2008;18:1202-9.

Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol. 2006;101:255-60.

Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol. 2009;113:75-82.

Desfeux P, Camatte S, Chatellier G, Blanc B, Querleu D, Lécuru F. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol. 2005;98:390-5.

Park HJ, Kim DW, Yim GW, Nam EJ, Kim S, Kim YT. Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. Am J Obstet Gynecol. 2013;209:58.e1-8.

Fagotti A, Fanfani F, Ludovisi M, Lo Voi R, Bifulco G, Testa AC, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol.2005;96:729-35.

Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199:642.e1-6.

Fagotti A, Vizzielli G, Fanfani F, Costantini B, Ferrandina G, Gallotta V, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol. 2013;131:341-6.

Covens AL, Dodge JE, Lacchetti C, Elit LM, Le T, Devries-Aboud M, et al. Surgical management of a suspicious adnexal mass: A systematic review. Gynecol Oncol. 2012;126:149-56.

Brockbank EC, Harr y V, Kolomainen D, Mukhopadhyay D, Sohaib a., Bridges JE, et al. Laparoscopic staging for apparent early stage ovarian or fallopian tube cancer. First case series from a UK cancer centre and systematic literature review. Eur J Surg Oncol. 2013;39:912-7.

Berek JS, Hacker NF. Gynecologic Oncology. 5th edition. Philadelphia: Lipincott Williams & Wilkins; 2010.

Timmers PJ, Zwinderman K, Coens C, Vergote I, Trimbos JB. Lymph Node Sampling and Taking of Blind Biopsies Are Important Elements of the Surgical Staging of Early Ovarian Cancer. Int J Gynecol Cancer. 2010;20:1142-7.

García-Soto AE, Boren T, Wingo SN, Heffernen T, Miller DS. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol. 2012;206:242.e1-5.

Shroff R, Brooks R a, Zighelboim I, Powell MA, Thaker PH, Mutch DG, et al. The Utility of Peritoneal Biopsy and Omentectomy in the Upstaging of Apparent Early Ovarian Cancer. Int J Gynecol Cancer. 2011;21:1.

Elias KM, Labidi-Galy SI, Vitonis AF, Hornick JL, Doyle LA, Hirsch MS, et al. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecol Oncol. 2014 132:328-33.

Feigenberg T, Covens A, Ghorab Z, Ismiil N, Dubé V, Saad RS, et al. Is routine appendectomy at the time of primary surgery for mucinous ovarian neoplasms beneficial? Int J Gynecol Cancer. 2013;23:1205-9.

Lin JE, Seo S, Kushner DM, Rose SL. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013;208:46.e1-4.

Ramírez PT, Slomovitz BM, McQuinn L, Levenback C, Coleman RL. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol. 2006;103:888-90.

Guvenal T, Dursun P, Hasdemir PS, Hanhan M, Guven S, Yetimalar H, et al. Effect of surgical staging on 539 patients with borderline ovarian tumors: A Turkish Gynecologic Oncology Group study. Gynecol Oncol. 2013;131:546-50.

Benacerraf BR, Finkler NJ, Wojciechowski C, Knapp RC. Sonographic accuracy in the diagnosis of ovarian masses. J Reprod Med. 1990;35:491-5.

Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility – sparing therapy. Gynecol Oncol. 2002;87:1-7.

Ayhan A, Celik H, Taskiran C, Bozdag G, Aksu T. Oncologic and reproductive outcome after fertility - saving surgery in ovarian cancer. Eur J Gynaecol Oncol 2003;24:223-32.

Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, et al. Optimal treatment of early-stage ovarian cancer. Ann Oncol. 2014;25:1165-71.

Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO. Interventions for the treatment of borderline ovarian tumors. Cochrane Database Syst Rev. 2010;(9):CD007696.

Morice P, Denschlag D, Rodolakis A, Reed N, Schneider A, Kesic V, et al. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer. 2011;21:951-63.

Messalli EM, Grauso F, Balbi G, Napolitano A, Seguino E, Torella M. Borderline ovarian tumors: Features and controversial aspects. Eur J Obstet Gynecol Reprod Biol. 2013;167:86-9.

Yinon Y, Beiner ME, Gotlieb WH, Korach Y, Perri T, Ben-Baruch G. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Fertil Steril. 2007;88:479-84.

Lenhard MS, Mitterer S, Kümper C, Stieber P, Mayr D, Ditsch N, et al. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol. 2009;145:189-94.

Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol. 2011;123:511-6.

Kleppe M, Bruls J, van Gorp T, Massuger L, Slangen BFM, van de Vijver KK, et al. Mucinous borderline tumors of the ovary and the appendix: A retrospective study and overview of the literature. Gynecol Oncol.2014;133:155-8.

Colombo N, Parma G, Lapresa MT, Maggi F, Piantanida P, Maggioni a. Role of conservative surg in ovarian cancer: the European experience. Int J Gynecol Cancer. 2005;15(Suppl 3):206-11.

Marpeau O, Schilder J, Zafrani Y, Uzan C, Gouy S, Lhommé C, et al. Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer. Ann Surg Oncol. 2008;15:478-83.

Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1-7.

Schlaerth AC, Chi DS, Poynor EA , Barakat RR, Brown CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:1199-204.

Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: A proposal for patient selection. J Clin Oncol. 2010;28:1727-32.

Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Nawa A, et al. Long-term sur vival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 2011;105:1288-94.

Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115:4118-26.

Kajiyama H, Shibata K, Suzuki S, Ino K, Nawa A, Kawai M, et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol. 2010;36:404-8.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083-90.

Ang C, Chan KKL, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane database Syst Rev. 2011;(4):CD007697.

Gerestein CG, Damhuis RAM, Burger CW, Kooi GS. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol. 2009;114:523-7.

Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559-64.

Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2007;106:69-74.

Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzin. Cancer.2009;115:1234-44.

Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119:259-64.

Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Neugut AI, et al. Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2011;123:467-73.

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane database Syst Rev. 2011;(8):CD007565.

Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a metaanalysis. Gynecol Oncol. 2013;130:493-8.

Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265-74.

Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2:CD008765.

Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 2010;21:75-80.

Schorge JO, Wingo SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynecol Obstet. 2010;108:123-7.

Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933-9.

Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102:656-62.

Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K, Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer. 2005;92:1026-32.

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTCNCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124:10-4.

Kang S, Nam B-H. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16:2315-20.

Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;(4):CD006014.

Nezhat FR, Pejovic T, Finger TN, Khalil SS. Role of Minimally Invasive Surgery in Ovarian Cancer. J Minim Invasive Gynecol. 2013;20:754-65.

Jaaback K, Johnson N, Lawrie T. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev.2011;(11):CD005340.

Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 2007;109:692-702.

Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. 2007;17:561-70.

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med. 2006;354:34-43.

Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015;136:130-5.

Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637-45.

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study. Ann Surg Oncol. 2015;22:1570-5. doi: 10.1245/s10434-014-4157-9. Epub 2014 Nov 13.

Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet.2010;376:1155-63.

Clarke T, Galaal K, Bryant A, Naik R. Evaluation of follow – up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews 2014, Issue 9. Art No. CD006119.

Chen YM, Chen T, Zee CS, Shi YP, Wan LR, Tong LJ. Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center. Nucl Med Commun. 2014;35:347-52.

Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and metaanalysis. Eur J Radiol. 2009;71:164-74.

Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2013; 23:598-607.

Kim CY, Jeong SY, Chong GO, Son SH, Jung JH, Kim DH, et al. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol. 2015;136:498-504.

Rustin GJ, van der Burg ME, MRC OVO, EORTC Collaborators. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) [abstract]. J Clin Oncol 2009;27(Suppl 18S): Abstract.

Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews 2011, Issue 6.

Geurts SME, de Vegt F, van Altena AM, van Dijck JAAM, Tjan-Heijnen VCG, Verbeek ALM, et al. Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2011;21:837-45.

Lajer H, Jensen MB, Kilsmark J, Albaek J, Svane D, Mirza MR, et al. The value of gynecologic cancer follow-up: evidence-based ignorance? Int J Gynecol Cancer 2010;20:1307-20.

National Comprehensive Cancer Network. Palliative Care. Version 2.2013.

Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database of Syst Rev. 2000: CD001219.

Ketcham AS, Hoye RC, Pilch YH, Morton DL. Delayed intestinal obstruction following treatment for cancer. Cancer. 1970;25:406-10.

Rubin SC, Hoskins WJ, Benjamin I, Lewis JL Jr. Palliative surger y for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol. 1989;34:16-9.

van Ooijen B, van der Burg ME, Planting AS, Siersema PD, Wiggers T. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet. 1993;176:469-74.

Lau PW, Lorentz TG. Results of surgery for malignant bowel obstruction in advanced, unresectable, recurrent colorectal cancer. Dis Colon Rectum. 1993;36:61-4.

Feuer DJ, Broadley KE, Shepherd JH, Barton DP. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(4):CD002764.


comments powered by Disqus

DOI: http://dx.doi.org/10.18597/rcog.385

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2016 Revista Colombiana de Obstetricia y Ginecología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN Impreso       0034-7434 

ISSN Electrónico   2463-0225

https://doi.org/10.18597/issn.0034-7434